[Financial management of clinical cardiovascular research in France from 1985 to 1990].
From 1985 to 1990, 31.5 MF were distributed for clinical cardiovascular research in France by: the Institut national de la santé et de la recherche médicale (INSERM): 7.7 MF (25%); the Société Française de cardiologie (SFC): 4.6 MF (15%) comprising 3.4 MF from its own resources (74%) and 1.2 MF from the pharmaceutical industry (26%); the Fédération Française de cardiologie (FFC): 9.4 MF (30%) comprising 6.4 MF (68%) from its own resources and 3 MF from the pharmaceutical industry (32%); the pharmaceutical industry directly: the Searle Foundation; 4.8 MF (15%); and the Bank Crédit Lyonnais: 5 MF (15%). The pharmaceutical industry therefore donated directly or indirectly via the SFC or the FFC, 9 MF or one third of the total sum attributed for cardiovascular research. Globally, over the period 1985-1990, the sums invested in cardiovascular research have doubled. The largest increase was related to the efforts of cardiologists themselves and their professional institutes: the SFC (by a factor of 3.7) and the FFC (by a factor of 2.5). On the other hand, independent donations and grants received from the pharmaceutical industry, the bank and Inserm have remained at the same level.
André-Fouët
X
X
Hôpital cardiovasculaire et pneumologique Louis-Pradel, Lyon.
D002309:Cardiology; D005376:Financial Management; D005602:France; D005653:Fund Raising; D006801:Humans; D017149:Private Sector; D017150:Public Sector; D012109:Research Support as Topic / Q000191:economics* / Q000458:organization & administration; D012955:Societies, Medical
Financement de la recherche cardiovasculaire clinique en France, de 1985 à 1990.